Atara Investors Get May 22 Deadline to Seek Lead Role in Securities Suit

Overview

• Law Offices of Howard G. Smith is inviting investors with losses in Atara Biotherapeutics to seek the lead plaintiff role, with motions due May 22, 2026.
• The putative class covers buyers of Atara stock from May 20, 2024 through January 9, 2026, according to the filings.
• The complaint alleges Atara failed to reveal manufacturing problems and weaknesses in its single-arm ALLELE study that made approval of its EBVALLO application unlikely.
• Atara disclosed on January 12, 2026 that the FDA issued a Complete Response Letter for EBVALLO, saying the ALLELE data could not support accelerated approval because design, conduct, and analysis confounded results, and the stock fell 56.99% that day.
• EBVALLO is a T-cell therapy for a rare post-transplant cancer tied to Epstein-Barr virus, and multiple firms are now recruiting shareholders on a contingency basis that charges no fees unless there is a recovery.